user
menu
letter
Sign InRegister
langEnglisharrow

Anti-SARS-CoV-2 Nucleocapsid Antibody-A5134, Human IgG1 (Trehalose free) (MALS verified)

Cat. No. / Size
Price
Availability
Qty
NUN-M507-100ug
$450.00
Inquire about delivery time
NUN-M507-1mg
$2,960.00
Inquire about delivery time
NUN-M507
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources

  • Source

    Anti-SARS-CoV-2 Nucleocapsid Antibody-A5134, Human IgG1 is isolated from a Nucleocapsid protein infected Human and is recombinantly produced from human 293 cells (HEK293).

  • Clone

    A5134

  • Isotype

    Human IgG1 | Human Kappa

  • Conjugate

    Unconjugated

  • Antibody Type

    Recombinant Monoclonal

  • Reactivity

    Virus

  • Specificity

    This product is a specific antibody specifically reacts with Nucleocapsid protein.

  • Application

    Application
    Recommended Usage
    ELISA
    0.1-5 ng/mL

  • Purity

    95% as determined by SDS-PAGE.

    90% as determined by SEC-MALS.

  • Purification

    Protein A purified / Protein G purified

  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, pH7.4.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Background

Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68). The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool.